06.12.2021 • NewsLonza

Lonza and Bioqube in Biologics Pact

Swiss CDMO Lonza has agreed a five-year collaboration on the development and manufacturing of biologics and small molecules with European venture capital firm Bioqube Ventures.

Under the terms of the deal, Lonza will support Bioqube Ventures during the due diligence of candidate biotechs and provide a tailored offering of advice and services to its portfolio companies. It will offer its expertise and technology on molecules ranging from monoclonal antibodies, complex proteins and small molecules to antibody-drug conjugates.

“This framework agreement provides Bioqube Ventures and its portfolio companies with a range of services for its late discovery and early development needs. Our customized and scalable solutions demonstrate our commitment to enabling emerging biotechs to take their drug candidates to the clinic,” said Pnina Weitz, global head of venture capital business development & relationship management at Lonza.

The partners said the holistic approach to drug substance and drug product development and manufacturing across various platforms significantly simplifies the supply chain, reduces process complexity and allows for shortened development timelines.

Author: Elaine Burridge, Freelance Journalist

(c) Lonza
(c) Lonza

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.